Archive - 2009
23 September 2009 - Press Releases
Karus Therapeutics and Queen Mary, University of London announce PI3 kinase collaboration
Karus Therapeutics Ltd, a company developing small molecule drugs to treat cancer and inflammation, has today announced that it has signed an agreement to collaborate with Professor Bart Vanhaesebroeck, at Queen Mary, University of London. Prof. Vanhaesebroeck is Centre Lead of the RAE 4-star rated Cell Signalling Laboratory. As part of the collaboration, Karus and Professor Vanhaesebroeck will be working to develop new small molecule inhibitors of selected isoforms of phosphoinositide 3-kinases (PI3K).
17 August 2009 - Press Releases
Karus CSO to present at three industry conferences
Innovative pharmaceutical company Karus Therapeutics Ltd has today announced that the company’s CSO, Dr Stephen Shuttleworth, will be making presentations at three key conferences in the coming weeks.
01 June 2009 - Press Releases
Organ transplant rejection collaboration with University Hospital Birmingham
Innovative pharmaceutical company Karus Therapeutics has today announced a collaborative research program with the Queen Elizabeth Hospital Renal Transplant Unit under the supervision of Lead Surgeon, Andrew Ready, Consultant Surgeon, Nicholas Inston, and Stephen Shuttleworth, CSO of Karus. The research program is designed to investigate the in vitro mechanisms-of-action of histone deacetylase inhibitors (HDIs) in specific leukocyte subsets, allogenic responses and in vivo models of transplant rejection.
04 May 2009 - Press Releases
KTP award with King's College
Innovative pharmaceutical company Karus Therapeutics Ltd has today announced the successful receipt of a Knowledge Transfer Partnership (KTP) award with King’s College London. The award will be used to support a collaborative program at the internationally renowned St John’s Institute of Dermatology at Guy’s Hospital under the joint supervision of the Head of Clinical Immunodermatology, Dr Richard Groves, and Dr Stephen Shuttleworth, Chief Scientific Officer of Karus Therapeutics. The KTP award will provide three years research and development support to Karus’s dermatology program.
06 April 2009 - Press Releases
Karus announces second closing of investment
Innovative pharmaceutical company Karus Therapeutics Ltd has today announced a second closing of its December 2008 investment, bringing the total amount raised to over £1 million and securing the company’s first US-based investor, New Hill Management LLC.
07 January 2009 - Press Releases
Karus Therapeutics secures investment
Innovative pharmaceutical company Karus Therapeutics Ltd has today announced the closing of a £0.9 million investment. Investors include IP Venture Fund, Esperante, Drummond Paris and a number of Business Angels. The investment will be used to advance the development of new drugs to treat cancer and inflammatory diseases such as rheumatoid arthritis and psoriasis and includes innovative medicines based on Karus’s HDAC inhibitor (HDI) platform.
Progress in the design and development of phosphoinositide 3-kinase (PI3K) inhibitors for the treatment of chronic diseases.
Shuttleworth S, Silva F, Tomassi C, Cecil A, Hill T, Rogers H, Townsend P.
Prog Med Chem. 2009, 48, p81-131.